Advertisement
JNJ vs NVS
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- JNJ delivered 5.9% revenue growth in its latest quarter and raised full-year guidance, yet shares fell as a slower medical-technology segment disappointed investors.
- NVS is navigating the largest patent expiration in its history, with blockbuster drugs such as Entresto facing generic competition in the U.S.
- Both companies are leaning on next-generation growth drivers: oncology and immunology franchises for JNJ, and Kisqali, Kesimpta, Pluvicto, and Leqvio for NVS.
- Novartis has faced sharper, deal-driven volatility, including two late-stage trial failures that wiped billions from its market value in a single week.
- Johnson & Johnson carries a more diversified model spanning pharmaceuticals and medical devices, while Novartis is a purer innovative-medicines play.
Introduction
Healthcare investors weighing diversified stability against a focused pharmaceutical franchise often land on this pairing: JNJ (Johnson & Johnson) and NVS (Novartis AG). Both are global leaders with strong dividend pedigrees, deep pipelines, and exposure to oncology and immunology, yet their market positioning and recent momentum have diverged meaningfully. This stock comparison examines relative performance, growth drivers, and risk factors to help traders and longer-term investors understand where each name stands in the current environment.
JNJ Overview and Recent Performance
Johnson & Johnson is a diversified healthcare conglomerate spanning two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). In its latest quarterly report, total sales rose 5.9% to roughly $25.4 billion, while adjusted earnings per share (EPS) of $2.59 topped consensus estimates. The pharmaceutical arm was the clear strength, growing 7.7% on standout performances from Tremfya, Caplyta, and Darzalex, which helped offset a steep decline in Stelara as it faces biosimilar competition.
Despite the beat, shares sold off in recent trading because the MedTech division grew only 2.5% and missed expectations across all four of its sub-segments. Management pointed to Middle East tensions, European spending cuts, and pricing pressure in China as headwinds, and signaled it may spin off its orthopedics business to sharpen focus. The company still raised its full-year outlook and declared a quarterly dividend, underscoring its defensive, cash-generating profile.
NVS Overview and Recent Performance
Novartis AG is a Swiss-based, pure-play innovative medicines company concentrated in four therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. In its most recent quarter, net sales grew about 3% (1% at constant currencies) to $14.4 billion, with core EPS beating estimates. Growth drivers Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio collectively expanded 36% at constant currencies, while aging franchises such as Entresto and Xolair posted sharp declines from generic and biosimilar competition.
Sentiment around NVS has been more volatile than its peer's. Positive late-stage results for the multiple-sclerosis candidate remibrutinib lifted shares, but two back-to-back late-stage trial failures—pelacarsen in cardiovascular disease and del-desiran in myotonic dystrophy—triggered one of the stock's steepest weekly declines in years and prompted a prominent shareholder to call for board-level changes. The company reaffirmed low single-digit sales growth guidance for the year.
Trending AI Robots
For traders seeking a systematic edge across names like JNJ and NVS, Tickeron's Trending AI Robots page offers a curated view of its marketplace. Tickeron hosts hundreds of AI trading bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of covered securities. Because not every bot fits every market regime, only those best suited to current conditions earn a place in the Trending AI Robots section. This allows users to scan high-conviction automated strategies rather than the full catalog. Explore the Trending AI Robots page to see which bots are currently favored.
Head-to-Head Comparison
The clearest structural contrast is diversification. JNJ pairs a high-margin pharmaceutical franchise with a sizable medical-device business, smoothing volatility but capping pure-play exposure. NVS is a focused innovative-medicines company, which offers sharper upside when the pipeline succeeds and deeper drawdowns when trials fail.
Growth profiles differ too. JNJ is generating solid pharmaceutical momentum while working through a MedTech slowdown and evaluating a potential orthopedics separation. Novartis is past a major patent cliff in Entresto but must prove its next-generation brands and late-stage pipeline can sustain growth after two high-profile trial setbacks. On sentiment, JNJ holds a comparatively defensive, income-oriented posture, while NVS carries higher event risk tied to clinical readouts and acquisition execution. Both face pricing pressure abroad and generic erosion at home, but the magnitude and timing of those risks differ meaningfully.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely tilt toward JNJ in the current environment. Its trend profile is comparatively steadier, supported by consistent pharmaceutical growth, a defensive dividend, and a diversified revenue base—even as MedTech softness tempers near-term momentum. NVS offers compelling long-term pipeline potential and strong growth-brand momentum, but recent trial failures and shareholder scrutiny introduce greater variability that AI models may treat as a near-term negative. The assessment is probabilistic: it favors the stability and relative positioning of JNJ today, while acknowledging that a re-acceleration in Novartis's pipeline could shift that balance over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Hold and NVS is a Hold.
JNJ sees its Stochastic Oscillator recovers from oversold territory
On October 09, 2026, the Stochastic Oscillator for JNJ moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 50 instances where the indicator left the oversold zone. In 25 of the 50 cases the stock moved higher in the following days. This puts the odds of a move higher at over 50%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 13 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 45%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 36 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 43%.
JNJ moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
The Aroon Indicator for JNJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.710) is normal, around the industry mean (19.199). P/E Ratio (31.549) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. JNJ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
NVS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVS's RSI Indicator exited the oversold zone, 15 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 37 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.720) is normal, around the industry mean (19.199). P/E Ratio (22.187) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). Dividend Yield (0.032) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
JNJ | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 7 | |
SMR RATING 1..100 | 37 | 33 | |
PRICE GROWTH RATING 1..100 | 45 | 45 | |
P/E GROWTH RATING 1..100 | 10 | 21 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as JNJ (12). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as NVS (7). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
NVS's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as JNJ (45). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (10) in the Pharmaceuticals Major industry is in the same range as NVS (21). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
| JNJ | NVS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 45% | 4 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 50% | 2 days ago 41% |
| Momentum ODDS (%) | 2 days ago 43% | 2 days ago 46% |
| MACD ODDS (%) | N/A | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 40% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 44% | 2 days ago 51% |
| Advances ODDS (%) | 6 days ago 46% | 2 days ago 54% |
| Declines ODDS (%) | 13 days ago 40% | 12 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 45% | 2 days ago 32% |
| Aroon ODDS (%) | 2 days ago 39% | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- JNJ’s TA Score: 4 bullish, 5 bearish.
- NVS’s TA Score: 6 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -2.25% price change this week, while NVS (@Pharmaceuticals: Major) price change was +4.78% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.91%. For the same industry, the average monthly price growth was -4.47%, and the average quarterly price growth was +3.55%.
Reported Earning Dates
JNJ is expected to report earnings on Jan 26, 2027.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.91% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with ABBV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then ABBV could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.